Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

NCT06441214

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia Alessandria, Italy
  • A.O.U. Ospedali Riuniti - Clinica di Ematologia Ancona, Italy
  • Ospedale C. e G. Mazzoni - U.O.C. di Ematologia Ascoli Piceno, Italy
  • AOU Policlinico Consorziale - U.O. Ematologia con Trapianto Bari, Italy
View all 28 locations
View Trial Details
Active, Not Recruiting

Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

NCT04882475

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • ASST Grande Ospedale Metropolitano Niguarda Milan, MI, Italy
  • AOU Senese - U.O.C. Ematologia Siena, SI, Italy
  • Centro Riferimento Oncologico - S.O.C. Oncologia Medica A Aviano, Italy
  • ASST Spedali Civili di Brescia - Ematologia Brescia, Italy
View all 16 locations
View Trial Details
Active, Not Recruiting

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

NCT05228158

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Eisai Trial Site 131 Komaki-shi, Aichi-ken, Japan
  • Eisai Trial Site 199 Konan-shi, Aichi-ken, Japan
  • Eisai Trial Site 21 Nagakute-shi, Aichi-ken, Japan
  • Eisai Trial Site 106 Nagoya, Aichi-ken, Japan
View all 135 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Medstar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • University of Miami Miami, Florida, United States
View all 72 locations
View Trial Details

Related conditions